✔️ SOLACI-SBHCI 2023 – International Live Case | TAVI for Pure Aortic Valve Regurgitation Using a Newself-Expanding Technology ✔️ Site: Nanjing First Hospital, Nanjing, China ✔️ August 4, 2023, Copacabana Room, Windsor Oceánico
Heterotopic Solution for TRICUSPID REGURGITATION – SOLACI-SBHCI 2023 – National Live Case
✔️ SOLACI-SBHCI 2023 – National Live Case | Heterotopic solution for tricuspid regurgitation ✔️ Site: INSTITUTO ESTADUAL DE CARDIOLOGIA ALOYSIO DE CASTRO (IECAC) ✔️ August 2, 2023, Copacabana Room, Windsor Oceánico
Health Status Scores after Transcatheter Repair in Patients with Tricuspid Regurgitation: TRILUMINATE Analysis
Severe tricuspid regurgitation (TR) has been associated with higher mortality and significant limitations to patient quality of life, with considerable rates of hospitalization for cardiac failure (CF). Transcatheter edge-to-edge repair (TEER) with TriClip has been shown effective to reduce symptoms, with low risk of periprocedural complications. The aim of this study was to assess functional...
Tricuspid Regurgitation: Natural Progression and Prognosis
The prevalence of tricuspid regurgitation (TR) is significant; its prognosis is well known, and severe TR stages are associated with higher mortality and hospitalization for cardiac failure (CF). Seeing as valve disease tends to evolve over time, in advanced stages, we usually check on patients at specified intervals for early identification of potential hemodynamic complications...
New Advances in Mitral Regurgitation Devices with Promising Results
Mitral regurgitation (MR) is a frequent valvulopathy and when the optimal medical treatment at maximum tolerated doses is not enough, surgery is the first course of action. And even though edge-to-edge repair with clips has seen substantial improvement, it is currently reserved for those at high risk of surgery. However, there is an increasing number...
TCT 2023 | CLASP IID Study 1-Year Results: PASCAL vs. MITRACLIP for Degenerative Mitral Regurgitation
The negative impact of mitral regurgitation (MR) on patient mortality, morbidity, and quality of life is widely recognized. However, only 15% of patients are referred for surgery due to their high surgical risk and low ejection fraction. Transcatheter edge-to-edge repair has become an important alternative for this group of patients. For subjects with degenerative MR,...
Degenerative Mitral Regurgitation: Impact on Post-Procedural Gradient
Primary or degenerative mitral regurgitation (MR) occurs frequently. Even though surgery continues to be the standard treatment at present, it remains risky for one group of patients, which makes edge-to-edge mitral valve repair (MV-TEER) a viable alternative. We are well aware that moderate to severe MR is associated with worse prognosis. However, post procedural mean...
MyVal Device in Non-Calcified Severe Aortic Regurgitation
Due to the proven long-term results and substantial increase in the number of transcatheter aortic valve implantation (TAVI) procedures conducted, the application of TAVI has been extended to clinical situations outside the original scope, such as non-calcified aortic regurgitation (NCAR). Device placement in these new scenarios entails a technical challenge due to the absence of...
New Devices for Percutaneous Treatment of Native Aortic Regurgitation: Expanding Horizons
Severe aortic regurgitation (AR) may account for 20% to 30% of all surgical aortic valve replacements (SAVR) and is often associated with aortic stenosis (AS). Transcatheter treatment of these patients is limited due to anatomical factors such as root and annular dilation, large annular dimensions, and less calcification in the valve leaflets to serve as...
Latest Developments in Tricuspid Regurgitation
The natural history of tricuspid regurgitation is associated to hospitalization for cardiac failure and mortality. This is why the AHA/ACC guidelines recommend surgery when the tricuspid fails during left valve surgical repair, because its slow progression is associated with high mortality (35%). Many of these patients are high risk and percutaneous intervention has surged as...